{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:18:42Z","timestamp":1788866322580,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Instituto Ramon y Cajal de Investigaci\u00f3n Sanitaria","award":["2021\/0453"],"award-info":[{"award-number":["2021\/0453"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12022-025-09894-9","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T01:23:15Z","timestamp":1764897795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multi-center Assessment of DLL3 Expression by Immunohistochemistry in Medullary Thyroid Carcinoma"],"prefix":"10.1007","volume":"36","author":[{"given":"Ignacio","family":"Ruz-Caracuel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Gerykov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Martins","family":"Gama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Rodr\u00edguez-Villena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Mart\u00ednez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Ryska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Eloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"9894_CR1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/his.15141","volume":"84","author":"YA Aksoy","year":"2024","unstructured":"Aksoy YA, Xu B, Viswanathan K et al. (2024) Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma. Histopathology 84: 947\u2013959","journal-title":"Histopathology"},{"key":"9894_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/thy.2023.0279","volume":"34","author":"B Xu","year":"2024","unstructured":"Xu B, Viswanathan K, Ahadi MS et al. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study (2024) Thyroid 34: 167\u2013176","journal-title":"Thyroid"},{"key":"9894_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2023.0482","volume":"34","author":"S Censi","year":"2024","unstructured":"Censi S, Galuppini F, Clausi C et al. (2024) Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma. Thyroid 34: 177\u2013185","journal-title":"Thyroid"},{"key":"9894_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.21.01329","volume":"40","author":"B Xu","year":"2022","unstructured":"Xu B, Fuchs TL, Ahmadi S et al. (2022) International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. J Clin Oncol 40: 96\u2013104","journal-title":"J Clin Oncol"},{"key":"9894_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA et al. (2022) Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 33: 27\u201363","journal-title":"Endocr Pathol"},{"key":"9894_CR6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1089\/thy.2019.0531","volume":"30","author":"N Qu","year":"2020","unstructured":"Qu N, Shi X, Zhao JJ et al. (2020) Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma. Thyroid 30: 1025\u20131036","journal-title":"Thyroid"},{"key":"9894_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12022-024-09817-0","volume":"35","author":"I Ruz-Caracuel","year":"2024","unstructured":"Ruz-Caracuel I, Caniego-Casas T, Alonso-Gordoa T et al. (2024) Transcriptomic Differences in Medullary Thyroid Carcinoma According to Grade. Endocr Pathol 35: 207\u2013218","journal-title":"Endocr Pathol"},{"key":"9894_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.omto.2021.02.004","volume":"20","author":"A Schwendenwein","year":"2021","unstructured":"Schwendenwein A, Megyesfalvi Z, Barany N et al. (2021) Molecular profiles of small cell lung cancer subtypes: therapeutic implications. Mol Ther Oncolytics 20: 470\u2013483","journal-title":"Mol Ther Oncolytics"},{"key":"9894_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","volume":"8","author":"AG Serrano","year":"2024","unstructured":"Serrano AG, Rocha P, Freitas Lima C et al. (2024) Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol 8: 268","journal-title":"NPJ Precis Oncol"},{"key":"9894_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12022-025-09854-3","volume":"36","author":"M Schmitt","year":"2025","unstructured":"Schmitt M, Bohnenberger H, Bartsch DK et al. (2025) DLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms. Endocr Pathol 36: 9","journal-title":"Endocr Pathol"},{"key":"9894_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-025-09873-0","volume":"36","author":"I Ahmed","year":"2025","unstructured":"Ahmed I, Mohamed A, Savari O, Xue Y, Asa SL (2025) Expression of DLL3 and SEZ6 in the Spectrum of Neuroendocrine Neoplasia. Endocr Pathol 36: 27","journal-title":"Endocr Pathol"},{"key":"9894_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","volume":"147","author":"F Rojo","year":"2020","unstructured":"Rojo F, Corassa M, Mavroudis D et al. (2020) International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer 147: 237\u2013243","journal-title":"Lung Cancer"},{"key":"9894_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","volume":"5","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS, Hong DS, Hann CL et al. (2021) A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol 5: 74","journal-title":"NPJ Precis Oncol"},{"key":"9894_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EC-20-0611","volume":"10","author":"M Ingenwerth","year":"2021","unstructured":"Ingenwerth M, Brandenburg T, Fuhrer-Sakel D et al. (2021) DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas. Endocr Connect 10: 283\u2013289","journal-title":"Endocr Connect"},{"key":"9894_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13000-019-0827-z","volume":"14","author":"L Brcic","year":"2019","unstructured":"Brcic L, Kuchler C, Eidenhammer S et al. (2019) Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures. Diagn Pathol 14: 47","journal-title":"Diagn Pathol"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09894-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:26:01Z","timestamp":1767860761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09894-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9894"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09894-9","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ignacio Ruz-Caracuel has received lecture fees and travel reimbursement from Lilly. Teresa Alonso-Gordoa has received research funding, honoraria, and nonfinancial support from IPSEN, Adacap, Pfizer, Sanofi, EISAI, Lilly, Bayer, Janssen, BMS, Astellas, Novartis, Roche, and MSD. Catarina Eloy has consulted in the last two years for Diapath, Sakura, Biocartis, Paige AI, and Epredia. Catarina Eloy serves as a member of the Editorial Board of Endocrine Pathology. All other authors declare that they have no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}